Annual Accounts Receivable
$21.18 M
+$4.53 M+27.23%
31 December 2023
Summary:
Travere Therapeutics annual accounts receivable is currently $21.18 million, with the most recent change of +$4.53 million (+27.23%) on 31 December 2023. During the last 3 years, it has risen by +$5.25 million (+32.99%). TVTX annual accounts receivable is now at all-time high.TVTX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$25.17 M
+$704.00 K+2.88%
30 September 2024
Summary:
Travere Therapeutics quarterly accounts receivable is currently $25.17 million, with the most recent change of +$704.00 thousand (+2.88%) on 30 September 2024. Over the past year, it has increased by +$10.60 million (+72.75%). TVTX quarterly accounts receivable is now at all-time high.TVTX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TVTX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +27.2% | +72.8% |
| 3 y3 years | +33.0% | +88.3% |
| 5 y5 years | +67.3% | +50.0% |
TVTX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +33.1% | at high | +98.7% |
| 5 y | 5 years | at high | +67.3% | at high | +112.2% |
| alltime | all time | at high | +166.1% | at high | >+9999.0% |
Travere Therapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $25.17 M(+2.9%) |
| June 2024 | - | $24.47 M(+7.6%) |
| Mar 2024 | - | $22.73 M(+7.3%) |
| Dec 2023 | $21.18 M(+27.2%) | $21.18 M(+45.4%) |
| Sept 2023 | - | $14.57 M(-28.6%) |
| June 2023 | - | $20.40 M(-5.3%) |
| Mar 2023 | - | $21.54 M(+29.4%) |
| Dec 2022 | $16.65 M(+4.6%) | $16.65 M(+31.4%) |
| Sept 2022 | - | $12.67 M(-24.1%) |
| June 2022 | - | $16.69 M(+13.7%) |
| Mar 2022 | - | $14.68 M(-7.8%) |
| Dec 2021 | $15.91 M(-0.1%) | $15.91 M(+19.0%) |
| Sept 2021 | - | $13.37 M(+12.7%) |
| June 2021 | - | $11.86 M(-9.2%) |
| Mar 2021 | - | $13.07 M(-18.0%) |
| Dec 2020 | $15.93 M(-11.8%) | $15.93 M(+6.0%) |
| Sept 2020 | - | $15.03 M(+6.7%) |
| June 2020 | - | $14.08 M(-22.2%) |
| Mar 2020 | - | $18.09 M(+0.2%) |
| Dec 2019 | $18.05 M | $18.05 M(+7.6%) |
| Sept 2019 | - | $16.78 M(+8.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2019 | - | $15.45 M(+21.5%) |
| Mar 2019 | - | $12.71 M(+0.4%) |
| Dec 2018 | $12.66 M(-8.7%) | $12.66 M(-5.9%) |
| Sept 2018 | - | $13.45 M(+9.1%) |
| June 2018 | - | $12.32 M(-5.1%) |
| Mar 2018 | - | $12.98 M(-6.4%) |
| Dec 2017 | $13.87 M(-25.1%) | $13.87 M(-4.6%) |
| Sept 2017 | - | $14.54 M(+9.2%) |
| June 2017 | - | $13.32 M(-13.7%) |
| Mar 2017 | - | $15.43 M(-16.7%) |
| Dec 2016 | $18.51 M(+48.6%) | $18.51 M(+23.8%) |
| Sept 2016 | - | $14.96 M(-9.7%) |
| June 2016 | - | $16.57 M(+23.6%) |
| Mar 2016 | - | $13.40 M(+7.6%) |
| Dec 2015 | $12.46 M(+56.5%) | $12.46 M(-7.7%) |
| Sept 2015 | - | $13.50 M(+17.7%) |
| June 2015 | - | $11.47 M(+40.5%) |
| Mar 2015 | - | $8.16 M(+2.5%) |
| Dec 2014 | $7.96 M | $7.96 M(+70.2%) |
| Sept 2014 | - | $4.68 M(+192.1%) |
| June 2014 | - | $1.60 M(+5458.3%) |
| Mar 2014 | - | $28.80 K |
FAQ
- What is Travere Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Travere Therapeutics?
- What is Travere Therapeutics annual accounts receivable year-on-year change?
- What is Travere Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Travere Therapeutics?
- What is Travere Therapeutics quarterly accounts receivable year-on-year change?
What is Travere Therapeutics annual accounts receivable?
The current annual accounts receivable of TVTX is $21.18 M
What is the all time high annual accounts receivable for Travere Therapeutics?
Travere Therapeutics all-time high annual accounts receivable is $21.18 M
What is Travere Therapeutics annual accounts receivable year-on-year change?
Over the past year, TVTX annual accounts receivable has changed by +$4.53 M (+27.23%)
What is Travere Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of TVTX is $25.17 M
What is the all time high quarterly accounts receivable for Travere Therapeutics?
Travere Therapeutics all-time high quarterly accounts receivable is $25.17 M
What is Travere Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, TVTX quarterly accounts receivable has changed by +$10.60 M (+72.75%)